Creative Biosciences (Guangzhou) CO., Ltd. (hereinafter referred to as CreativeBio) has made another solid stride on its path toward globalization. Colosafe^®, the company's core product, has successfully obtained market entry in 42 countries and regions across Asia, Europe, South America, and Africa, which has initiated market promotion and substantial sales collaborations to achieve widespread market coverage. This milestone demonstrates the company's strong momentum in the global market, let alone reflects the solid strength in research and development alongside innovation capabilities.

Colosafe^®, as the first stool DNA test for colorectal cancer approved for market in China, can accurately identify the risk of colorectal cancer, providing strong support for the early prevention and treatment of the disease. With its excellent performance and user-friendly sample collection, it has obtained global recognition and praise. Notably, on September 2, 2024, the product successfully acquired registration approval in Brazil, marking the beginning of a new chapter in the South American market.

Since 2023, CreativeBio has been actively expanding its business to outside of mainland China, establishing subsidiaries in Hong Kong, Berlin, and Seattle. This establishment covers key markets in Southeast Asia, Europe, Middle East, and the Americas, providing endorsement for the promotion of the company’s products and services worldwide.

Since its foundation, CreativeBio has always regarded technological research and innovation as its lifeline. Founded with dedication by Dr. Hongzhi Zou, a renowned scientist and entreprenuer, the company has successfully attracted top talents domestically and internationally to form a powerful R&D team devoted to in-depth research in early cancer screening and diagnostic technologies. In addition to Colosafe®, more methylation detection tests for lung, bladder, and liver cancer, together with point-of-care testing devices are in development and have achieved remarkable breakthroughs. The broad product pipeline offers more diverse health testing options to global consumers.

Looking ahead, CreativeBio is determined to adhere to its core strategy of research and innovation, constantly exploring new detection technologies and products in the life science field. Guided by the human health needs, the company is committed to providing more high-quality, efficient health products and services, contributing to the advancement of a global community of human health.